China earmarks special bonds for data infrastructure
China will elevate the amount and proportion of fiscal subsidies this year to support local governments and industries to build a number of data infrastructure projects. — China Daily
Beijing: China will step up the input of central funds to support the construction of data infrastructure and make full use of ultra-long-term special treasury bonds to accelerate the building of architecture related to national data infrastructure, says the National Data Administration (NDA), the country's top data governance regulator.
Experts said the country's latest move to construct data infrastructure will bolster the circulation, development and utilisation of data resources, facilitate high-quality growth of the country's digital economy and unleash the value of massive data elements.
China will elevate the amount and proportion of fiscal subsidies this year to support local governments and industries to build a number of data infrastructure projects that are basic and long-term and benefit the general public, said the NDA on Monday.
It will also speed up efforts to study and formulate plans concerning national data infrastructure during the 15th Five-Year Plan from 2026 to 2030.
National data infrastructure refers to a new type of infrastructure that supports data collection, aggregation, transmission, processing, circulation, utilisation, operation and security.
It comes amid the backdrop of the rapid development of digital technologies and infrastructure across the globe.
Liu Liehong, head of the NDA, said the administration will initiate construction of the main structure of national data infrastructure this year, and quicken the establishment of relevant standards.
It will also strengthen exchanges and cooperation with international organisations to absorb experience in the construction of data infrastructure worldwide.
Liu said the plan regarding national data infrastructure will focus on four aspects: data circulation and utilisation facilities, computing power facilities, network facilities, and security facilities.
China aims to complete the building of the main structure of national data infrastructure by 2029, according to a guideline jointly issued by the National Development and Reform Commission, the NDA and the Industry and Information Technology Ministry in January.
The guideline stated that efforts will be made to complete the top-level design of national data infrastructure between 2024 and 2026. Such infrastructure will support large-scale data circulation and interconnectivity, while integrating data networks and computing power facilities between 2027 and 2028.
The country has also vowed to upgrade the 5G network to 5G-advanced or 5G-A, a crucial upgrade of the 5G network in terms of functionality and coverage and promote 6G-related research, development and innovation. — China Daily/ANN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
11 hours ago
- Malaysian Reserve
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 6, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the 'Class Period'), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen as well as certain of UroGen's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. The UroGen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. The UroGen class action lawsuit further alleges that on May 16, 2025, the FDA published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's NDA for UGN-102, which stated that '[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret,' and that the FDA had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock fell nearly 26%, according to the complaint. Then, on May 21, 2025, the UroGen class action lawsuit further alleges that the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk of the investigation therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock fell nearly 45%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UroGen securities during the Class Period to seek appointment as lead plaintiff in the UroGen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UroGen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UroGen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UroGen class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
The Sun
4 days ago
- The Sun
UK nuclear site could leak until 2050s, MPs warn
LONDON: Britain's most hazardous building threatens to leak radioactive water until the 2050s unless the clean-up of a former nuclear power plant is quickened, UK lawmakers warned on Wednesday. The waste has been leaking into the ground from a storage silo at the Sellafield facility in Cumbria, in northwest England, since 2018 -- enough to fill an Olympic-sized swimming pool every three years. Sellafield, which began operations in the 1940s, generated nuclear power between 1956 and 2003. In a report published Wednesday, a group of British MPs criticised the pace of the decommissioning work, citing examples of 'failure, cost overruns and continuing safety concerns'. It said the risks were highlighted by the Magnox Swarf Storage Silo (MSSS), described by Sellafield owner the Nuclear Decommissioning Authority (NDA) as 'the most hazardous building in the UK'. The report by the Public Accounts Committee found that most of the annual targets for retrieving waste from buildings at the site, including the MSSS, had been 'missed'. It said the storage silo is likely to continue leaking until the oldest section of the building has been emptied in the late 2050s, instead of 2040 as previously expected. 'Every day at Sellafield is a race against time to complete works before buildings reach the end of their life,' said the committee's chair, Geoffrey Clifton-Brown. 'Our report contains too many signs that this is a race that Sellafield risks losing,' he added, saying the site presented 'intolerable risks'. The radioactive leak is contained and does not pose a risk to the public, the report noted. A spokeswoman for the NDA said fixing it was the group's 'highest priority'. Britain's National Audit Office forecast last October that the cost of decommissioning and cleaning up the entire Sellafield site over the next century had soared to £136 billion ($177 billion). This was up almost 19 percent on the previous official estimate made in 2019. It noted that 'full site remediation' was not expected until 2125.
The Sun
4 days ago
- The Sun
Chinese researchers charged with smuggling fungus into US
WASHINGTON: Two Chinese scientists have been charged with allegedly smuggling a toxic fungus into the United States that they planned to research at an American university, the Justice Department said Tuesday. Yunqing Jian, 33, and Zunyong Liu, 34, are charged with conspiracy, smuggling, false statements, and visa fraud, the US Attorney's Office for the Eastern District of Michigan said in a statement. Jian is in US custody while Liu's whereabouts are unknown. The Justice Department said the pair conspired to smuggle a fungus called Fusarium graminearum into the United States that causes 'head blight,' a disease of wheat, barley, maize, and rice. The fungus is classified in scientific literature as a 'potential agroterrorism weapon,' it said, and causes billions of dollars in losses each year. It causes vomiting, liver damage, and reproductive defects in humans and livestock, it said. According to the complaint, Jian and Liu, her boyfriend, had both previously conducted work on the fungus in China. '(Liu) first lied but then admitted to smuggling Fusarium graminearum into America... so that he could conduct research on it at the laboratory at the University of Michigan where his girlfriend, Jian, worked,' the Justice Department said. US Attorney Jerome Gorgon Jr described the smuggling of the fungus into the United States as a 'national security' concern and emphasized Jian's membership in the Chinese Communist Party. 'These two aliens have been charged with smuggling a fungus that has been described as a 'potential agroterrorism weapon' into the heartland of America, where they apparently intended to use a University of Michigan laboratory to further their scheme,' Gorgon said. Chinese foreign ministry spokesman Lin Jian said he was not aware of the case when asked for comment at a regular news briefing on Wednesday. 'The Chinese government has always required Chinese citizens overseas to strictly abide by local laws and regulations, and at the same time safeguards the legitimate rights and interests of Chinese citizens overseas in accordance with the law,' he said. US Secretary of State Marco Rubio vowed last week to 'aggressively revoke visas' for Chinese students, a move condemned by Beijing as 'unreasonable' and 'discriminatory.' Kseniia Petrova, a scientist from Russia at Harvard, is facing potential deportation after she failed to declare biological samples in her luggage upon returning from a trip to Paris.
